Asco 2020 – after Tecentriq’s liver win the spotlight falls on Merck and Astra
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.
Asco 2020 – Bavencio “cure” suggests another cancer target for immunotherapy
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.
Asco 2020 – Tagrisso shows what early targeting can do
With an 83% reduction in the risk of disease recurrence in early-stage lung cancer, Astrazeneca’s Tagrisso takes the top spot at Asco.
US regulator scoops Asco with Bristol’s lung cancer approval
The green light comes two months early, revealing data that were being held back for Asco, but what does Yervoy bring to the table?
Careful label reading reveals more Lynparza doubts
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
Lynparza’s prostate cancer surprise
An unexpectedly broad prostate cancer label gives the Parp inhibitor a strong advantage over Clovis’s rival Rubraca.
Lynparza nod confirms a leg up for Glaxo
As the battle between Parp inhibitors for front-line ovarian cancer intensifies, biomarker testing and Avastin biosimilars will play a role.
Empliciti’s front-line flop underlines Darzalex’s dominance
The CS1 approach to treating multiple myeloma was once thought capable of matching CD38, but that train left the station some time ago.
Karyopharm comes to Boston for the springtime
Karyopharm’s newly approved myeloma drug, Xpovio, has shown promise in earlier lines of therapy, but toxicity could still cap its potential.
